We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring CVS' Health Services Segment: A Key Growth Engine for 2025?
Read MoreHide Full Article
Key Takeaways
CVS' Health Services revenues rose 8% year over year to over $43B, led by specialty pharmacy strength.
Caremark will list Wegovy as a preferred GLP-1 drug and expand access via CVS retail pharmacies.
CVS incurred a $247M loss tied to its exit from ACO REACH and MSSP in Q1 2025.
Healthcare conglomerate CVS Health (CVS - Free Report) formed its Health Services segment through a realignment tied to a new operating model adopted in early 2023. In its last reported quarter, the segment contributed more than $43 billion in revenues — up 8% year over year — driven by growth in specialty pharmacy, higher pricing of branded medications and pharmacy drug mix. However, these gains were partially offset by ongoing price improvements extended to pharmacy clients.
The segment includes CVS Caremark, one of the leading pharmacy benefit managers (PBM) in the United States, which helps curb drug spend through its solutions without compromising quality care. Starting July 1, Caremark will list Novo Nordisk’s (NVO - Free Report) Wegovy as the preferred GLP-1 medicine on its largest commercial template formularies. The Novo Nordisk partnership echoes CVS’ launch of a low-cost Humira biosimilar via its Cordavis subsidiary, which now leads the U.S. market. CVS will also serve as the first retail pharmacy in NVO’s NovoCare pharmacy network, increasing Wegovy’s access at 9,000 community health locations.
In the first quarter of 2025, CVS Health processed more than $464 million of pharmacy claims on a 30-day equivalent basis, with membership reaching almost 88 million as of March-end. In the healthcare delivery business, growth continues to be led by the performance of Oak Street and Signify Health assets. Still, persistently elevated Medicare Advantage remains a concern for Oak Street Health’s growth.
Meanwhile, CVS exited the Accountable Care Organization Realizing Equity, Access and Community Health (“ACO REACH”) program and sold its Medicare Shared Savings Program (“MSSP”) business to Wellvana Health, incurring a combined loss of $247 million in the first quarter. Still, analysts continue to remain bullish on the segment, with the Zacks Consensus Estimate indicating a 4.6% increase in Health Services revenues over 2024.
What About CVS’ Peers?
The Cigna Group (CI - Free Report) is gaining from the strength of its Evernorth Health Services portfolio. Within this, CI reported 14% year-over-year growth in Pharmacy Benefit Services in the first quarter of 2025, mainly from existing client relationships and new businesses. Strong specialty volume growth in Cigna’s Specialty and Care Services drove an 18.9% improvement. Organic growth in specialty businesses was supported by higher Humira biosimilar adoption.
At Humana (HUM - Free Report) , the CenterWell segment, which includes the company’s pharmacy, primary care and home solutions operations, reported a 37.5% increase in service revenues in the first quarter of 2025. Humana reduced operating costs in this segment owing to its value creation initiatives and also benefited from more favorable operating trends in the primary care business. Still, HUM saw some of the improvement being offset by the impact of the v28 risk model revision.
CVS’ Price Performance, Valuation and Estimates
Year to date, CVS Health shares have surged 49.4% against the industry’s 0.2% dip.
Image Source: Zacks Investment Research
In terms of valuation, CVS is trading at a forward 12-month price-to-sales of 0.22X compared to the industry average of 0.41X. The stock’s Value Score of A further adds to its appeal.
Image Source: Zacks Investment Research
Consensus estimates for CVS Health’s 2025 earnings have been trending upward over the past 90 days.
Image: Bigstock
Exploring CVS' Health Services Segment: A Key Growth Engine for 2025?
Key Takeaways
Healthcare conglomerate CVS Health (CVS - Free Report) formed its Health Services segment through a realignment tied to a new operating model adopted in early 2023. In its last reported quarter, the segment contributed more than $43 billion in revenues — up 8% year over year — driven by growth in specialty pharmacy, higher pricing of branded medications and pharmacy drug mix. However, these gains were partially offset by ongoing price improvements extended to pharmacy clients.
The segment includes CVS Caremark, one of the leading pharmacy benefit managers (PBM) in the United States, which helps curb drug spend through its solutions without compromising quality care. Starting July 1, Caremark will list Novo Nordisk’s (NVO - Free Report) Wegovy as the preferred GLP-1 medicine on its largest commercial template formularies. The Novo Nordisk partnership echoes CVS’ launch of a low-cost Humira biosimilar via its Cordavis subsidiary, which now leads the U.S. market. CVS will also serve as the first retail pharmacy in NVO’s NovoCare pharmacy network, increasing Wegovy’s access at 9,000 community health locations.
In the first quarter of 2025, CVS Health processed more than $464 million of pharmacy claims on a 30-day equivalent basis, with membership reaching almost 88 million as of March-end. In the healthcare delivery business, growth continues to be led by the performance of Oak Street and Signify Health assets. Still, persistently elevated Medicare Advantage remains a concern for Oak Street Health’s growth.
Meanwhile, CVS exited the Accountable Care Organization Realizing Equity, Access and Community Health (“ACO REACH”) program and sold its Medicare Shared Savings Program (“MSSP”) business to Wellvana Health, incurring a combined loss of $247 million in the first quarter. Still, analysts continue to remain bullish on the segment, with the Zacks Consensus Estimate indicating a 4.6% increase in Health Services revenues over 2024.
What About CVS’ Peers?
The Cigna Group (CI - Free Report) is gaining from the strength of its Evernorth Health Services portfolio. Within this, CI reported 14% year-over-year growth in Pharmacy Benefit Services in the first quarter of 2025, mainly from existing client relationships and new businesses. Strong specialty volume growth in Cigna’s Specialty and Care Services drove an 18.9% improvement. Organic growth in specialty businesses was supported by higher Humira biosimilar adoption.
At Humana (HUM - Free Report) , the CenterWell segment, which includes the company’s pharmacy, primary care and home solutions operations, reported a 37.5% increase in service revenues in the first quarter of 2025. Humana reduced operating costs in this segment owing to its value creation initiatives and also benefited from more favorable operating trends in the primary care business. Still, HUM saw some of the improvement being offset by the impact of the v28 risk model revision.
CVS’ Price Performance, Valuation and Estimates
Year to date, CVS Health shares have surged 49.4% against the industry’s 0.2% dip.
Image Source: Zacks Investment Research
In terms of valuation, CVS is trading at a forward 12-month price-to-sales of 0.22X compared to the industry average of 0.41X. The stock’s Value Score of A further adds to its appeal.
Image Source: Zacks Investment Research
Consensus estimates for CVS Health’s 2025 earnings have been trending upward over the past 90 days.
Image Source: Zacks Investment Research
CVS stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.